Home
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Today’s Highlights March 16, 2026

Structure Therapeutics in the NEWS

SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) - Structure Therapeutics Inc. (GPCR), today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.

In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
March 16, 2026

Other Articles